Hot Features
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobrom... Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -0.684931506849 | 2.92 | 3.0673 | 2.75 | 877889 | 2.85964108 | CS |
| 4 | 0.38 | 15.0793650794 | 2.52 | 3.08 | 2.37 | 808105 | 2.77855283 | CS |
| 12 | 0.32 | 12.4031007752 | 2.58 | 3.08 | 2.21 | 544034 | 2.67764231 | CS |
| 26 | 0.61 | 26.6375545852 | 2.29 | 3.08 | 2.1 | 409265 | 2.55267961 | CS |
| 52 | 0.26 | 9.84848484848 | 2.64 | 3.22 | 1.8 | 617210 | 2.49750794 | CS |
| 156 | 1.12 | 62.9213483146 | 1.78 | 3.22 | 0.5052 | 649768 | 2.17793877 | CS |
| 260 | -11.41 | -79.7344514326 | 14.31 | 19.87 | 0.5052 | 917075 | 2.29645948 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.